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Fig. 1. Plots illustrating in vitro interference of DIGIBIND or DigiFab with 
13  digoxin imm unoassays.
Group A (p a n e ls  A 1 -A 4 )  includes m ethods with marked interference; group B 
(p a n e ls  B 1 -B 4 )  includes m ethods with m oderate interference; and group C 
(p a n e ls  C l  and C2) includes m ethods with minimal interference. Within each 
group, p a n e ls  1  or 3  represent a ssay s  performed on sam ples treated with 
DIGIBIND, p a n e ls  2  or 4  represent a ssay s  performed on sam ples treated with 
DigiFab. Within groups A and B, p a n e ls  1  or 2  represent a ssay s  in the absence 
of digoxin, p a n e ls  3  or 4  rep resen t a ssay s  in the  p resence of 4 0  n g /L  digoxin. 
In group C (p a n e ls  C l  and C2), only da ta  obtained in the presence of 40  n g /L  
digoxin are shown with ultrafiltrates (UF) for the TDx and AxSYM assays.
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Digoxin is widely prescribed for the treatment of cardiac 
conditions (7). Because of its narrow therapeutic range, 
digoxin-related toxicity resulting from acute or chronic 
overdose is common. Metabolites of digoxin as well as 
related compounds, including digitoxin, tanshinones, bu- 
fandienolide, and oleander, can contribute to or indepen­
dently produce digoxin toxicity (2,3). Digoxin toxicity 
can be rapidly and safely reversed by administration of 
anti-digoxin immune fragments (Fab) such as DIG­
IBIND'19, which has been available in the US since 1986. 
Therapeutic Fab products act by binding digoxin with 
high affinity (10 —1010 L/mol), favoring movement of 
digoxin out of tissue and thus promoting elimination. 
Factors that impact dosing with Fab products include 
known or suspected digoxin load, patient weight and 
history, and renal function (4-7).
Monitoring the free digoxin concentration after Fab 
administration may help ensure appropriate dosing, pre­
vent deadly recrudescent toxicity, and determine when 
digoxin therapy should be resumed (8-10). Monitoring 
free digoxin in serum is challenged by the positive inter­
ference that has been extensively described with DIGI­
BIND, which interferes with immunoassays by competing 
with assay capture antibodies. The degree of interference 
depends on incubation times, washing steps, and the 
affinity of capture antibody for bound vs free digoxin 
(77-73). Consequently, monitoring of free digoxin in 
ultrafiltrates is a popular strategy for managing DIGI- 
BIND-treated patients. Although ultrafiltration eliminates
interference produced by large molecules, such as endog­
enous digoxin-like immunoreactive factors (DLIFs) and 
DIGIBIND, it does not eliminate interferences produced 
by small molecules known to interfere with digoxin 
immunoassays, such as spironolactone (74). In addition, 
ultrafiltration methods are not standardized, may require 
matrix-specific calibration, add expense and manual ma­
nipulation, and lengthen turnaround time (8,15,16).
DigiFab™ is a Fab preparation that was approved by 
the Food and Drug Administration in 2001 for treating 
potentially life-threatening digoxin toxicity or overdose. 
Fab is produced by immunization of sheep with digoxin 
(DIGIBIND) or digoxindicarboxymethylamine (DigiFab), 
followed by purification of the Fab from blood. The 
approximate molecular weights of DigiFab (46 000) and 
DIGIBIND (46 200) are similar, and a single vial of either 
DIGIBIND or DigiFab will bind —0.5 mg of digoxin in 
vivo. As such, the clinical claims, dosing recommenda­
tions, and administration of DigiFab are identical to those 
of DIGIBIND. However, clinical studies have monitored 
DigiFab therapy by measuring digoxin in ultrafiltrates 
only (77). The present study was designed to determine 
whether clinically relevant concentrations of DigiFab in 
serum interfere with 13 digoxin immunoassays and to 
compare results with DIGIBIND.
Single vials of DIGIBIND (38 mg; Glaxo Wellcome Inc.) 
and DigiFab (40 mg; Protherics, Inc.) were dissolved in 4 
mL of type 1 water. DIGIBIND and DigiFab were added 
to pooled drug-free and DLIF-free serum to obtain final 
concentrations of 0.1, 0.8, 2, 8, and 16 m g/L. Increasing 
concentrations of each antidote (1, 2, 4, 8, and 16 mg/L) 
were also combined with 40 jug/L digoxin (Sigma- 
Aldrich) in pooled serum. Ultrafiltrates were prepared by 
use of Millipore Centrifree filters (30 kDa) and a fixed- 
angle centrifuge rotor (2000g for 30 min at ambient 
temperature). Prepared samples were aliquoted and 
stored frozen (—70 °C) until analyzed, a practice that 
should not affect the ability of DIGIBIND to bind digoxin 
(18).
Digoxin was measured by 13 commercially available 
competitive immunoassays. Five homogeneous assays 
(Beckman-Coulter Synchron; Roche CEDIA, Integra, and 
TinaQuant; and Syva Emit 2000) and seven heterogeneous 
assays (Abbott AxSYM, Beckman-Coulter Access, Chiron 
ADVIA Centaur, Dade Behring Dimension RxL, DPC 
IMMULITE 2000, Ortho Vitros, and Roche Elecsys 2010) 
designed to quantify free digoxin in patient serum or 
plasma were evaluated. The CEDIA and TinaQuant as-
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says were performed on the Hitachi 917 platform, and the 
Hitachi 717 platform was used to perform the Emit assay. 
The Abbott TDx/TDxFLx assay, which measures total 
digoxin in patient serum or plasma, was also used. Assays 
were calibrated and performed according to manufactur­
ers' instructions, and three controls (Bio-Rad) were in­
cluded with each run. Although most assays were per­
formed with serum only, the TDx and AxSYM were 
performed with both serum and ultrafiltrate. Samples 
with values exceeding the reportable range of the assay 
were diluted and reassayed as recommended by the 
manufacturer. Plotted points represent a single result in 
most cases; points represent the average result when more 
than one result was obtained.
Positive interference in the presence and absence of 
digoxin was observed with DfGfBfND and DigiFab (Fig. 
1). Although interference was somewhat less with Digi­
Fab (Fig. 1, panels A2, A4, B2, and B4) compared with 
DfGfBfND (Fig. 1, panels Al, A3, Bl, and B3), these 
differences in magnitude are not likely to be clinically 
significant and may represent batch-specific differences 
(18). The magnitude of the interference varied consider­
ably with each method. As such, the methods were 
grouped as follows: group A (marked interference), fM- 
MULfTE, Vitros, Dimension, and Access methods; group 
B (moderate interference), Elecsys, TinaQuant, Integra, 
Emit, and Centaur methods; and group C (minimal inter­
ference), TDx, AxSYM, Synchron, and CEDfA methods. 
Interference in the absence of digoxin was observed at the 
lowest concentration of DfGfBfND tested (0.1 m g/L) with 
the IMMULITE (2.2 n g /L  digoxin measured), Vitros (1.5 
jug/L), and Dimension (0.9 ng/L)  methods, whereas 
higher concentrations of the antidotes were required to 
observe interference in other group A and B methods. The 
interference in all group A and B methods was concen­
tration-dependent and followed a linear relationship over 
the concentrations examined.
Interference was then evaluated in the presence of a 
digoxin concentration (40 jug/L) consistent with that 
observed clinically after a patient has been poisoned with 
digoxin (8,10,17).  Increasing concentrations of DfGf- 
BfND or DigiFab reduced the amount of digoxin mea­
sured in all but the TDx method. The TDx method, the 
only method used here that incorporates a preanalytical 
protein precipitation step, provides results that are most 
consistent with total digoxin concentration in the presence 
of therapeutic Fab (8,10). Some inaccuracy was observed 
with the TDx method, as indicated by the results shown in 
Fig. 1, panels C l and C2. The inaccuracy may be attrib­
uted to error introduced by manual dilution or by copre­
cipitation of digoxin with protein, a phenomenon sug­
gested to occur with high protein concentrations (12).
Data most consistent with free digoxin in the presence 
of Fab were obtained with ultrafiltrates (Fig. 1, panels C l 
and C2). The discrepancies in results observed at 1 m g/L  
Fab (Fig. 1, panels C l and C2) are curious. The predicted 
value of free digoxin at this concentration of Fab is 30 
Mg/L, which is similar to that seen with ultrafiltrates and 
with the CEDfA method. The reason that the AxSYM and 
Synchron methods modestly overestimated the digoxin 
concentration at this concentration of either DfGfBfND or 
DigiFab is unknown.
Equimolarity and consequent neutralization of 40 ng /L  
digoxin should be achieved with 4 m g/L  of either Fab 
product. Complete neutralization of digoxin was ob­
served with 4 or 8 m g/L  Fab in the AxSYM, Synchron, 
and CEDfA methods (Fig. 1C), but was not observed with 
those assays in groups A and B (Fig. 1, panels A3, A4, B3, 
and B4). With Fab concentrations >4 m g/L, unbound Fab 
(antidote excess) would be expected. Accordingly, the















A IMMULITE 0 .2 -8 .0 77 .4  (15 480%) 3.6  (206%) 7.9 (192%) 5 .4  (180%) 5.7 (1146%)
Vitros 0 .4 -4 .0 5 8 .0  (11 600%) 2.8  (159%) 6 .0  (147%) 4 .0  (133%) 3 .8  (760%)
Dimension 0 .0 6 -5 .0 2 6 .0  (5202%) 1.4 (82%) 2 .9  (70%) 2 .1  (71%) 1.8 (363%)
Access 0 .2 -6 .0 7 .9 (1572%) 2.3  (132%) 4 .9  (119%) 3 .4  (112%) 1.8 (352%)
B Elecsys 0 .1 5 -5 .0 2 .5  (504%) 3.0  (172%) 7.0 (172%) 4 .3  (143%) 3 .4  (680%)
TinaQuant 0 .1 5 -7 .5 3 .4  (680%) 3.0  (170%) 6 .9  (169%) 5 .3  (177%) 4 .4  (880%)
Integra 0 .1 3 -5 .0 2 .5  (500%) 2.9  (165%) 6 .0  (147%) 4 .7  (157%) 3 .2  (640%)
Emit 0 .2 -5 .0 3 .9  (780%) 3.5  (199%) 4 .4  (108%) 3 .5  (117%) 4 .4  (880%)
Centaur 0 .1 -5 .0 1.7 (330%) 2.7 (152%) 6 .2  (152%) 5 .0  (167%) 1.7 (344%)
C TDx 0 .5 -5 .0 23.7 7.5 12 .9 8 .4 33 .2
TDx UF'7 0 .5 -5 .0 < 0 .5 1.8 4 .1 3.0 0.5
AxSYM UF 0 .3 -4 .0 < 0 .3 1.9 4.2 2.8 0.5
AxSYM 0 .3 -4 .0 < 0 .3  (100%) 1.8 (104%) 4 .5  (110%) 4 .1  (137%) 1.3 (264%)
Synchron 0 .2 -5 .0 < 0 .2  (100%) 3.0  (168%) 6.7 (164%) 4 .1  (137%) 3.7 (730%)
CEDIA 0 .1 5 -4 .0 < 0 .1 5  (100%) 2.5  (142%) 5 .0  (123%) 3 .4  (113%) 1.3 (260%)
a Reportable ranges were obtained from the manufacturers.
b Values in parentheses are the percentage of the TDx ultrafiltrate, where <0.5 = 0.5. 
c UF, ultrafiltrate.
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digoxin measured by group A and B methods increased 
linearly with Fab concentrations >4 m g/L. No increase in 
digoxin was observed with group C methods. The data 
presented in Fig. 1 suggest that positive interference from 
unbound Fab should be expected with all group A and B 
methods. As such, accurate interpretation of free digoxin 
concentrations in samples containing near-equimolar an­
tidote or antidote excess requires evaluation of ultrafil­
trate or use of an assay with which the immunotherapeu- 
tic agent does not interfere. The mechanism of Fab 
interference in specific digoxin immunoassays may be 
attributable to differences in the affinity an d /o r specific­
ity of the capture antibodies used in each assay. It is of 
interest that the presence of a wash step (heterogeneous 
design) did not consistently prevent or minimize Fab- 
induced interference.
Because it is known that in vitro samples may not 
accurately represent samples collected in vivo (13), sam­
ples obtained from patients treated with DIGIBIND for 
digoxin toxicity were also evaluated. Residual patient 
serum was collected and pooled according to human 
subject guidelines approved by the Institutional Review 
Board (University of Utah). The data in Table 1 are 
expressed as measured digoxin (ng/L)  and as a percent­
age of the ultrafiltrate result from the TDx method, a 
method reported to be free of matrix bias and clinically 
demonstrated as suitable for monitoring DIGIBIND- 
treated patients (19). Results for ultrafiltrates obtained 
with the TDx method agreed well with results obtained 
for both serum and ultrafiltrates in the AxSYM method. 
Under conditions of DIGIBIND excess (Table 1, pool 1), a 
pattern of positive interference was observed that corre­
sponded well with the in vitro predictions derived from 
Fig. 1. Thus, total digoxin (TDx) was 23.7 ng/L,  whereas 
free digoxin was undetectable when evaluated with 
group C methods and in an ultrafiltrate. The highest 
concentrations of apparent digoxin were observed with 
the group A methods in a pattern consistent with that 
seen in vitro. Likewise, moderate but clinically significant 
overestimations of digoxin were observed with group B 
methods.
Under conditions of digoxin excess (Table 1, pools 2-4) 
or in the presence of equimolar digoxin and DIGIBIND 
(Table 1, pool 5), the extent of neutralization varied 
considerably with the method. Furthermore, the pattern 
of results was not consistent with that observed in vitro. 
For example, both the highest and lowest results for pools 
2-4 were observed with group A methods (IMMULITE 
and Dimension, respectively), methods for which marked 
interference was observed in vitro. For pool 5, digoxin 
results were overestimated by all methods compared with 
results obtained after ultrafiltration. Thus, results ob­
tained with group A methods were 352-1146% of the 
results obtained for ultrafiltrates, results with group B 
methods were 344-880% of the results obtained for 
ultrafiltrates, and results with group C methods were 
260-730% of the results obtained for ultrafiltrates. These 
data suggest that the degree of Fab-induced positive 
interference observed in vivo cannot be predicted solely
from in vitro data, particularly when the molar ratio of 
Fab to digoxin is s  1. A possible explanation for the 
difference in results between the in vitro and in vivo 
specimens is the contribution of digoxin metabolites and 
DLIFs to in vivo specimens. Such compounds would be 
extracted from tissue stores by Fab therapy and are likely 
to interfere with digoxin immunoassays, depending on 
the corresponding affinity of and reactivity with capture 
antibodies. Further research is required to fully character­
ize these interactions.
In conclusion, positive interference should be antici­
pated when samples from patients treated with either 
DIGIBIND or DigiFab are tested with any of the following 
digoxin immunoassays: Access, Synchron, Centaur, Di­
mension, IMMULITE, Vitros, Elecsys, CEDIA, Integra, 
TinaQuant, and Emit. Although minimal interference was 
observed with the AxSYM method, ultrafiltration remains 
the best strategy for accurate determination of free 
digoxin concentrations in the presence of therapeutic Fab 
products.
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